Yvonne Efebera, MDThe James Cancer Center
- Multiple Myeloma
- Graft vs Host Disease
- Waldenstrom Macroglobulinemia
- Bone Marrow Transplantation
- Stem Cell Transplantation
- Blood Cancers
Make an Appointment
My clinical focus at the OSUCCC – James is B-cell lymphoid malignancies, including multiple myeloma, amyloidosis, Waldenstrom's disease and stem cell and bone marrow transplant. I also serve as an associate professor of internal medicine for The Ohio State University. In 2014 and 2017, I was rated in the top 10 percent of physicians in the nation for patient satisfaction.
I regard my patients as part of my family. When I discuss their treatment with them, I often say that if they were my sister, my father or my mother I would recommend the same treatment. Every one of my patients knows they have a physician who deeply cares and has done her best to help them.
I’m also very passionate about research, and I study novel therapies for treating multiple myeloma and graft-versus-host disease (GVHD). The latter is a complication that can occur after a stem cell or bone marrow transplant in which the transplanted cells attack the body, often resulting in a serious illness.
One of the best things about working at The James is being surrounded by such outstanding scientists and clinicians. Everyone here is an expert in his or her area, and that in turn inspires me to become a better and more effective physician.
Education and Background
Pennsylvania State University College of Medicine
Cleveland Clinic Foundation
Boston Medical Center
Bone Marrow Transplant
MD Anderson Cancer Center
- American Board of Internal Medicine
- American Board of Internal Medicine (Subspecialty: Medicine Oncology)
- Department of Internal Medicine
- Division of Hematology
I see patients at
The James Cancer Hospital and Solove Research Institute
460 West 10th Avenue, Columbus, Ohio 43210
Consulting and Related Relationships
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 3/28/2017, Dr. Efebera has reported no financial relationships with medical device, research and/or drug companies.